MetaVia Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
MetaVia (market cap ~$3M) announced Q2 2026 results: all patients in Phase 1 Part 3 study of DA-1726 reached target doses (48 mg and 64 mg). The company reported 9.1% mean weight loss and 23.7% liver stiffness reduction at 48 mg after 8 weeks in prior Phase 1 data. Cash balance is $12.6M as of June 30, 2026 (vs. $10.3M at Dec 31, 2025). Net loss was $5.3M for Q2 2026 ($0.90/share on 5.9M diluted shares); R&D expenses increased $1.2M YoY to $3.5M. 16-week topline data from Part 3 expected Q4 2026.
Why this rating
DA-1726 dose escalation is a meaningful clinical milestone for a $3M-cap biotech, but is procedural execution rather than a new material result. Q4 data readout could be transformational; current event is a necessary step. Cash burn (~$9M/6mo) and reliance on clinical upside create inherent risk.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.